{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["43(1)"],"submitter":["Jirovec E"],"funding":["University of Helsinki"],"pubmed_abstract":["<h4>Background</h4>A limitation of approved oncolytic viruses is their requirement for intratumoral (i.t.) injection. TILT-123 (igrelimogene litadenorepvec, Ad5/3-E2F-D24-hTNFα-IRES-hIL-2) is a chimeric oncolytic adenovirus suitable for intravenous (i.v.) delivery due to its capsid modification and dual selectivity devices. It is armed with tumor necrosis alpha and interleukin-2 for promoting T-cell activation and lymphocyte trafficking to tumors, thereby enhancing the antitumor immune response. Here, we present the findings after a single i.v. administration of TILT-123 in three phase I dose escalation clinical trials.<h4>Methods</h4>Patients with advanced solid tumors initially received a single i.v. dose of TILT-123 ranging from 3 × 10<sup>9</sup> to 4 × 10<sup>12</sup> viral particles "],"journal":["Journal of experimental & clinical cancer research : CR"],"pagination":["297"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11539705"],"repository":["biostudies-literature"],"pubmed_title":["Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors."],"pmcid":["PMC11539705"],"pubmed_authors":["Alanko T","Khammari A","Cervera-Carrascon V","Block MS","Haybout L","Dreno B","Adamo DA","Svane IM","Kudling T","Quixabeira DCA","Jalkanen K","Arias V","Pakola SA","Hemminki O","Kanerva A","Maenpaa J","Kistler C","Santos JM","Monberg T","Sorsa S","Hemminki A","Jirovec E","Clubb JHA"],"additional_accession":[]},"is_claimable":false,"name":"Single intravenous administration of oncolytic adenovirus TILT-123 results in systemic tumor transduction and immune response in patients with advanced solid tumors.","description":"<h4>Background</h4>A limitation of approved oncolytic viruses is their requirement for intratumoral (i.t.) injection. TILT-123 (igrelimogene litadenorepvec, Ad5/3-E2F-D24-hTNFα-IRES-hIL-2) is a chimeric oncolytic adenovirus suitable for intravenous (i.v.) delivery due to its capsid modification and dual selectivity devices. It is armed with tumor necrosis alpha and interleukin-2 for promoting T-cell activation and lymphocyte trafficking to tumors, thereby enhancing the antitumor immune response. Here, we present the findings after a single i.v. administration of TILT-123 in three phase I dose escalation clinical trials.<h4>Methods</h4>Patients with advanced solid tumors initially received a single i.v. dose of TILT-123 ranging from 3 × 10<sup>9</sup> to 4 × 10<sup>12</sup> viral particles ","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024 Nov","modification":"2026-06-01T15:21:51.338Z","creation":"2025-04-06T10:12:02.175Z"},"accession":"S-EPMC11539705","cross_references":{"pubmed":["39506856"],"doi":["10.1186/s13046-024-03219-0"]}}